Siasos Gerasimos, Tsigkou Vasiliki, Kosmopoulos Marinos, Theodosiadis Dimosthenis, Simantiris Spyridon, Tagkou Nikoletta Maria, Tsimpiktsioglou Athina, Stampouloglou Panagiota K, Oikonomou Evangelos, Mourouzis Konstantinos, Philippou Anastasios, Vavuranakis Manolis, Stefanadis Christodoulos, Tousoulis Dimitris, Papavassiliou Athanasios G
Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Division of Cardiovascular, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ann Transl Med. 2018 Jun;6(12):256. doi: 10.21037/atm.2018.06.21.
Mitochondria are the source of cellular energy production and are present in different types of cells. However, their function is especially important for the heart due to the high demands in energy which is achieved through oxidative phosphorylation. Mitochondria form large networks which regulate metabolism and the optimal function is achieved through the balance between mitochondrial fusion and mitochondrial fission. Moreover, mitochondrial function is upon quality control via the process of mitophagy which removes the damaged organelles. Mitochondrial dysfunction is associated with the development of numerous cardiac diseases such as atherosclerosis, ischemia-reperfusion (I/R) injury, hypertension, diabetes, cardiac hypertrophy and heart failure (HF), due to the uncontrolled production of reactive oxygen species (ROS). Therefore, early control of mitochondrial dysfunction is a crucial step in the therapy of cardiac diseases. A number of anti-oxidant molecules and medications have been used but the results are inconsistent among the studies. Eventually, the aim of future research is to design molecules which selectively target mitochondrial dysfunction and restore the capacity of cellular anti-oxidant enzymes.
线粒体是细胞能量产生的来源,存在于不同类型的细胞中。然而,由于心脏对能量的高需求(通过氧化磷酸化实现),线粒体的功能对心脏尤为重要。线粒体形成大型网络,调节新陈代谢,而线粒体融合与线粒体分裂之间的平衡可实现其最佳功能。此外,线粒体功能通过线粒体自噬过程进行质量控制,该过程可清除受损细胞器。由于活性氧(ROS)的不受控制产生,线粒体功能障碍与多种心脏疾病的发生有关,如动脉粥样硬化、缺血再灌注(I/R)损伤、高血压、糖尿病、心脏肥大和心力衰竭(HF)。因此,早期控制线粒体功能障碍是心脏病治疗的关键步骤。已经使用了许多抗氧化分子和药物,但研究结果并不一致。最终,未来研究的目标是设计出能够选择性靶向线粒体功能障碍并恢复细胞抗氧化酶能力的分子。